Next-Gen Cancer Treatments: HER2-Mutated Breast Cancer, NSCLC ADCs, and FGFR Resistance cover art

Next-Gen Cancer Treatments: HER2-Mutated Breast Cancer, NSCLC ADCs, and FGFR Resistance

Next-Gen Cancer Treatments: HER2-Mutated Breast Cancer, NSCLC ADCs, and FGFR Resistance

Listen for free

View show details

About this listen

Love what you hear? Download the Curie app from the App Store today.

Curie is your personalized, expert-driven healthcare podcast platform—offering in-depth analysis, timely insights, and discussions tailored for medical professionals.

In this episode of Curie, Matt explores game-changing developments in oncology. Learn about the latest chemotherapy-free approach for HER2-mutated metastatic breast cancer, where tucatinib and trastuzumab are showing durable responses. Discover how datopotamab deruxtecan, a TROP2-directed antibody-drug conjugate, is offering new hope for EGFR-mutated and ALK-rearranged NSCLC patients. Finally, dive into groundbreaking insights on FGFR inhibitor resistance in cholangiocarcinoma—and how liquid biopsies could revolutionize treatment strategies. Stay informed and ahead of the curve with these cutting-edge updates in precision oncology!
activate_mytile_page_redirect_t1

What listeners say about Next-Gen Cancer Treatments: HER2-Mutated Breast Cancer, NSCLC ADCs, and FGFR Resistance

Average Customer Ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com.au reviews

Amazon Reviews
No Reviews are Available
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.